Australia markets close in 3 hours 56 minutes
  • ALL ORDS

    7,306.90
    -5.10 (-0.07%)
     
  • ASX 200

    7,047.20
    -8.20 (-0.12%)
     
  • AUD/USD

    0.7718
    +0.0011 (+0.14%)
     
  • OIL

    61.77
    +0.34 (+0.55%)
     
  • GOLD

    1,787.80
    +5.80 (+0.33%)
     
  • BTC-AUD

    65,286.23
    -5,801.96 (-8.16%)
     
  • CMC Crypto 200

    1,136.94
    -106.12 (-8.54%)
     
  • AUD/EUR

    0.6418
    +0.0010 (+0.16%)
     
  • AUD/NZD

    1.0768
    +0.0012 (+0.11%)
     
  • NZX 50

    12,592.11
    +14.63 (+0.12%)
     
  • NASDAQ

    13,762.36
    -172.79 (-1.24%)
     
  • FTSE

    6,938.24
    +42.95 (+0.62%)
     
  • Dow Jones

    33,815.90
    -321.41 (-0.94%)
     
  • DAX

    15,320.52
    +124.55 (+0.82%)
     
  • Hang Seng

    28,988.57
    +233.23 (+0.81%)
     
  • NIKKEI 225

    29,021.01
    -167.16 (-0.57%)
     

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

Verrica Pharmaceuticals
·1-min read

WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place March 9-10, 2021.

A pre-recorded presentation will be available for on-demand access beginning at 7:00 a.m. ET on Tuesday, March 9, 2021. Participants may access a webcast of the event through the following link:
https://journey.ct.events/view/920684dd-5942-496a-9960-f3619118a62d.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@troutgroup.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@troutgroup.com